Skip to main content
Swing Capital

Procter & Gamble Health Ltd

NSE: PGHL BSE: 500126

P&G Health Ltd (formerly Procter & Gamble td) (erstwhile Merck Limited) is engaged in the business of manufacturing and marketing of pharmaceuticals and chemicals.[1]

₹5,266
52W: ₹4700 — ₹6739
PE 29.8 · Book ₹373 · +1312% vs book
Market Cap₹8,740 Cr
Stock P/E29.8Price to Earnings
ROCE47.8%Return on Capital
ROE36.4%Return on Equity
Div. Yield2.37%Face Value ₹10

Strengths

  • +Company has reduced debt.
  • +Company is almost debt free.
  • +Company has a good return on equity (ROE) track record: 3 Years ROE 33.0%
  • +Company has been maintaining a healthy dividend payout of 67.5%

Weaknesses

  • −Stock is trading at 13.9 times its book value
  • −The company has delivered a poor sales growth of 0.16% over past five years.
  • −Debtor days have increased from 39.5 to 56.8 days.

Shareholding Pattern

Promoters51.82%
FIIs6.2%
DIIs13.67%
Public28.3%
CategoryJun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026
Promoters51.82%51.82%51.82%51.82%51.82%51.82%51.82%51.82%
FIIs6.39%6.61%▲0.27.01%▲0.46.86%▼0.16.99%▲0.17.24%▲0.36.97%▼0.36.2%▼0.8
DIIs14.56%14.84%▲0.314.71%▼0.114.21%▼0.514.15%▼0.113.9%▼0.313.84%▼0.113.67%▼0.2
Public27.24%26.74%▼0.526.47%▼0.327.11%▲0.627.03%▼0.127.05%▲0.027.37%▲0.328.3%▲0.9

Financial Statements

MetricSep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025
Sales305310252284313310311339325374
Expenses216208185236199186230248205263
Operating Profit8910267481141238190120110
OPM %29%33%27%17%36%40%26%27%37%30%
Net Profit66724717829161668978
EPS ₹39.543.4228.0510.1149.654.7636.8639.8753.3446.74

AI Insights

Revenue Trend

TTM revenue at ₹1,349Cr, up 44.4% YoY. OPM at 30%.

Debt Position

Borrowings at ₹6Cr. Debt-to-equity ratio: 0.01x. Healthy balance sheet.

Capex Cycle

CWIP at ₹13Cr (12% of fixed assets). Moderate ongoing capital expenditure.

Institutional Flow

DIIs: 13.67% (+1.38pp change). FIIs: 6.2% (-0.95pp change). Promoters hold 51.82%.

Margin & Efficiency

ROCE improving from 12% (Dec 2014) to 48% (Mar 2025). Working capital days: 48.

Valuation

PE 29.8x with 47.8% ROCE. Price is 1312% above book value of ₹373. Dividend yield: 2.37%.

Recent Announcements